Residual thrombin potential predicts cardiovascular death in acute coronary syndrome patients undergoing percutaneous coronary intervention

Introduction: Thrombin generation (TG) is a central step of the coagulation system involved in hemostatic and thrombotic roles. Scarce data evaluating in the acute phase the association between TG and the risk of cardiovascular death of acute coronary syndrome (ACS) patients are available, in the era of percutaneous coronary intervention (PCI) and stenting with the use of dual antiplatelet treatment. Materials and methods: We investigated TG in 292 ACS patients undergoing PCI with stent implantation on dual antiplatelet treatment. Venous samples were obtained 12-24 h after PCI. TG was assessed using the Calibrated Automated Thrombogram (CAT). Results: At two years of follow-up, 57 out of 292 patients (19.5%) died from cardiovascular causes. Higher values of endogenous thrombin potential (ETP) [1115.9 (705-1441.3) vs 940.2 (666.0-1253.1), p = 0.049], peak [176.1 (80.5-259.4) vs 107.3 (59.9-181.1), p = 0.002] and velocity index [61.75 (21.03-97.88) vs 25.64 (11.95-50.90), p < 0.001] were observed in relation to survival patients. At the multivariate model adjusted for the Global Registry of Acute Coronary Events risk score, the association between TG and cardiovascular death remained significant for ETP [OR (95% CI): 2.58 (1.10-6.03), p = 0.029], peak [OR (95% CI): 3.27 (1.35-7.92), p = 0.009] and velocity index [OR (95% CI): 3.06 (1.27-7.39), p = 0.013]. This result was confirmed after adjustment for high on-treatment platelet reactivity [ETP: OR (95% CI) 2.35 (1.11-5.00), p = 0.027; peak: OR (95% CI) 2.42 (1.13-5.15), p = 0.022; velocity index: OR (95% CI) 2.43 (1.14-5.20), p = 0.022]. Conclusions: ACS patients with a residual TG after PCI and stent implantation have a significantly higher risk of long-term cardiovascular death. These results might be useful in improving risk stratification for ACS patients and support the need of a tailored antithrombotic therapy. (C) 2016 Published by Elsevier Ltd.